var data={"title":"Selecting antiretroviral regimens for the treatment-na√Øve HIV-infected patient","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/contributors\" class=\"contributor contributor_credentials\">John G Bartlett, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/contributors\" class=\"contributor contributor_credentials\">Paul E Sax, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 01, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1195155\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of human immunodeficiency virus (HIV) infection involves the use of combination antiretroviral therapy (ART). Use of these multidrug regimens substantially reduces progression to AIDS, opportunistic infections, hospitalizations, and death. Drug selection could potentially include more than 25 antiretroviral medications available in six major classes; however, only a small proportion of these agents are recommended for initial therapy. </p><p>This topic will address the approach to choosing an initial ART regimen for treatment-na&iuml;ve patients with HIV-1. The treatment of patients with HIV-2 and the treatment of HIV-infected woman during pregnancy are discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-hiv-2-infection\" class=\"medical medical_review\">&quot;Treatment of HIV-2 infection&quot;</a> and <a href=\"topic.htm?path=antiretroviral-and-intrapartum-management-of-pregnant-hiv-infected-women-and-their-infants-in-resource-rich-settings\" class=\"medical medical_review\">&quot;Antiretroviral and intrapartum management of pregnant HIV-infected women and their infants in resource-rich settings&quot;</a>.)</p><p>Other topics relevant to the treatment of individuals with HIV include: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=when-to-initiate-antiretroviral-therapy-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;When to initiate antiretroviral therapy in HIV-infected patients&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=patient-monitoring-during-hiv-antiretroviral-therapy\" class=\"medical medical_review\">&quot;Patient monitoring during HIV antiretroviral therapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=selecting-an-antiretroviral-regimen-for-treatment-experienced-hiv-infected-patients-who-are-failing-therapy\" class=\"medical medical_review\">&quot;Selecting an antiretroviral regimen for treatment-experienced HIV-infected patients who are failing therapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1195261\"><span class=\"h1\">GOALS OF THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goals of antiretroviral therapy (ART) are to reduce HIV-related morbidity and mortality (from both infectious and noninfectious causes) and to prevent transmission of HIV to others. To achieve and sustain these goals, ART should result in maximal suppression of HIV RNA. Suppression of plasma viremia below the level of detection by commercial assays also prevents the selection of drug-resistant mutations and allows for improved immunologic function (as measured by the CD4 cell count). A discussion on the use of ART for prevention of HIV transmission is found elsewhere. (See <a href=\"topic.htm?path=hiv-infection-risk-factors-and-prevention-strategies\" class=\"medical medical_review\">&quot;HIV infection: Risk factors and prevention strategies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1263878448\"><span class=\"h1\">WHOM TO TREAT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We agree with guideline panels that recommend antiretroviral therapy (ART) be offered to all HIV-infected patients, including asymptomatic individuals, regardless of their immune status [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The only individuals in whom the benefits of ART are not proven are the small proportion of untreated patients with preserved CD4 cell counts and undetectable HIV RNA (sometimes referred to as HIV controllers). </p><p>For most individuals, we initiate ART soon after their initial diagnosis. Some studies suggest that initiating therapy at the initial visit increases the likelihood of starting therapy and retention in care [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/3\" class=\"abstract_t\">3</a>]. Special considerations for patients with opportunistic infections and other AIDS-related conditions are discussed elsewhere. (See <a href=\"topic.htm?path=when-to-initiate-antiretroviral-therapy-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;When to initiate antiretroviral therapy in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1195394\"><span class=\"h1\">ANTIRETROVIRAL AGENTS</span></p><p class=\"headingAnchor\" id=\"H1195401\"><span class=\"h2\">Drug classes used in treatment-na&iuml;ve patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are more than 25 antiretroviral medications from six major classes currently available for the management of HIV-infected patients (<a href=\"image.htm?imageKey=ID%2F60927\" class=\"graphic graphic_table graphicRef60927 \">table 1</a>). There are four classes of antiretroviral drugs typically used in initial regimens. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Protease inhibitors (PIs)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Integrase strand transfer inhibitors (INSTIs)</p><p/><p>The CCR5 antagonist (<a href=\"topic.htm?path=maraviroc-drug-information\" class=\"drug drug_general\">maraviroc</a>) is also available, but is generally not recommended for treatment-na&iuml;ve patients. The fusion inhibitor (<a href=\"topic.htm?path=enfuvirtide-drug-information\" class=\"drug drug_general\">enfuvirtide</a>) is only used for patients with multidrug-resistant virus. (See <a href=\"topic.htm?path=selecting-an-antiretroviral-regimen-for-treatment-experienced-hiv-infected-patients-who-are-failing-therapy#H105697182\" class=\"medical medical_review\">&quot;Selecting an antiretroviral regimen for treatment-experienced HIV-infected patients who are failing therapy&quot;, section on 'Fusion inhibitors'</a> and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3802481164\"><span class=\"h2\">Commonly used agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most commonly used agents for treatment-na&iuml;ve patients are summarized below and are described in greater detail elsewhere. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;</a>.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>NRTI combinations</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Tenofovir-emtricitabine</strong> &ndash; Tenofovir is administered orally as the prodrug <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF) or <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> (TAF). The intracellular, pharmacologically-active moiety is tenofovir-diphosphate, which is also active against hepatitis B virus. TDF and TAF are coformulated with <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>, as well as several different third agents (<a href=\"image.htm?imageKey=ID%2F60927\" class=\"graphic graphic_table graphicRef60927 \">table 1</a>). </p><p/><p class=\"bulletIndent2\"><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate-emtricitabine</a> <span class=\"nowrap\">(TDF/FTC)</span> is very well tolerated, and a number of well-designed studies have found that this combination is effective in suppressing HIV RNA when used with a variety of different third agents [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/4-8\" class=\"abstract_t\">4-8</a>]. However, TDF is associated with renal toxicity and should generally be avoided in patients with reduced kidney function (ie, estimated glomerular filtration rate &lt;60 <span class=\"nowrap\">min/mL/1</span>.73m<sup>2</sup>). </p><p/><p class=\"bulletIndent2\"><a href=\"topic.htm?path=tenofovir-alafenamide-and-emtricitabine-drug-information\" class=\"drug drug_general\">Tenofovir alafenamide-emtricitabine</a> <span class=\"nowrap\">(TAF/FTC)</span> became available in 2016. This agent has equivalent efficacy compared with <span class=\"nowrap\">TDF/FTC</span> and improved renal and bone safety [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/9-13\" class=\"abstract_t\">9-13</a>]. Unlike TDF, TAF can be used in most patients with moderately reduced kidney function [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"#H1195773\" class=\"local\">'Reduced kidney function'</a> below.)</p><p/><p class=\"bulletIndent2\">However, TAF is more susceptible to drug interactions that induce its metabolism and should be avoided in patients taking certain medications, such as rifamycins and some anticonvulsants. Refer to the drug interaction program within UpToDate to assess for specific interactions. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589706088\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Tenofovir'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">Abacavir-lamivudine</a> &ndash; Abacavir-lamivudine is another first-line NRTI combination. However, <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> is <strong>contraindicated</strong> in persons who test positive for HLA-B*5701 as they are at high risk for developing an abacavir hypersensitivity reaction. (See <a href=\"topic.htm?path=abacavir-hypersensitivity-reaction\" class=\"medical medical_review\">&quot;Abacavir hypersensitivity reaction&quot;</a>.)</p><p/><p class=\"bulletIndent2\">Although <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> has less kidney and bone toxicity compared with TDF, there are concerns about its use in patients with high viral loads (unless <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> is the third agent) and in those with, or at risk for, cardiovascular disease. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589706622\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Abacavir'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Integrase Strand Transfer Inhibitors</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">Raltegravir</a> &ndash; Raltegravir was approved for use in 2007, so among the INSTIs, there is the longest clinical experience with this agent. It also has the fewest drug-drug interactions in this class. For treatment-na&iuml;ve patients, it can be administered as either one 400 mg pill twice daily (800 mg total daily dose) or as two 600 mg pills once daily (1200 mg total daily dose) [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/14\" class=\"abstract_t\">14</a>]. Raltegravir is not coformulated as part of a single pill regimen. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589708487\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Raltegravir'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">Elvitegravir</a> &ndash; Elvitegravir was approved in 2012, and must be given with a pharmacologic boosting agent (eg, <a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a>) for once-daily administration. It is available in two coformulations, <a href=\"topic.htm?path=elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information\" class=\"drug drug_general\">elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide</a> and <a href=\"topic.htm?path=elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information\" class=\"drug drug_general\">elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate</a>. We prefer the coformulation that contains TAF, which can be administered to patients with moderately reduced kidney function. The coformulation that contains TDF should only be administered if the eGFR is &ge;70 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>. (See <a href=\"#H1291633581\" class=\"local\">'Preferred regimens'</a> below.)</p><p/><p class=\"bulletIndent2\">The coformulated tablets that include <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a> have the benefit of being a single pill regimen that can be administered once daily. However, the need for pharmacokinetic boosting results in the greatest number of significant drug-drug interactions among the INSTIs. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589708571\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Elvitegravir'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">Dolutegravir</a> &ndash; Dolutegravir was approved in 2013. For treatment-na&iuml;ve patients, it is given once daily, and is available as a single agent or as a coformulated tablet with <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> and <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a>. Dolutegravir was noninferior to <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> in a comparative clinical trial in treatment-na&iuml;ve patients [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/6\" class=\"abstract_t\">6</a>] and is generally well tolerated. </p><p/><p class=\"bulletIndent2\"><a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">Dolutegravir</a> resistance is very uncommon, even in the setting of virologic failure, suggesting it has a higher barrier to resistance than <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> or <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a>. Thus, this agent is well suited for those who require treatment before the results of genotype testing are available [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1\" class=\"abstract_t\">1</a>]. Additional reasons for using dolutegravir as the preferred third agent are described below. (See <a href=\"#H1195766\" class=\"local\">'Choosing a regimen'</a> below.)</p><p/><p class=\"bulletIndent2\">Despite the many advantages of <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a>, this agent may have increased neuropsychiatric side effects compared with other INSTIs, although they do not typically lead to treatment discontinuation [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/15,16\" class=\"abstract_t\">15,16</a>]. In addition, it has more drug interactions than <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> (eg, <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a>, anti-epileptics) but far fewer than <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a><span class=\"nowrap\">/<a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a></span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Protease inhibitors </strong>&ndash; PIs are typically administered in combination with a nucleoside combination; however, they can also be used as part of a <span class=\"nowrap\">nucleoside-sparing/limiting</span> regimen. PIs should be administered with a boosting agent such as <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a> or <a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a>. Although boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> and boosted <a href=\"topic.htm?path=atazanavir-drug-information\" class=\"drug drug_general\">atazanavir</a> are both effective as initial therapy in combination with a nucleoside backbone, boosted darunavir is generally preferred because it is better tolerated. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1322359219\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Protease inhibitors (PIs)'</a>.)</p><p/><p class=\"bulletIndent1\">Some of the class side effects of PIs are hyperglycemia, diabetes, and hyperlipidemia. In addition, the need for pharmacological boosting can result in significant drug interactions. However, PIs have a high barrier to developing resistance, and therefore, they are often well suited for patients who take their medications intermittently. (See <a href=\"#H3175441804\" class=\"local\">'Patients with adherence concerns'</a> below.) </p><p/><p class=\"headingAnchor\" id=\"H1195505\"><span class=\"h1\">CONSIDERATIONS PRIOR TO INITIATING TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients should start a regimen consisting of <a href=\"topic.htm?path=tenofovir-alafenamide-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir alafenamide-emtricitabine</a> with one of the integrase inhibitors (<a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a>, <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a> boosted with <a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a>, or <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a>) as the third drug. <a href=\"topic.htm?path=abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">Abacavir-lamivudine</a> may be used if the integrase inhibitor is dolutegravir. (See <a href=\"#H1291633581\" class=\"local\">'Preferred regimens'</a> below.)</p><p>To help determine which ART regimen is best for a particular patient, clinicians should take into account the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The patient&rsquo;s comorbid conditions and degree of organ dysfunction (eg, heart disease, osteoporosis, renal insufficiency, hepatitis B virus [HBV] infection, <span class=\"nowrap\">and/or</span> psychiatric conditions). (See <a href=\"topic.htm?path=initial-evaluation-of-the-hiv-infected-adult\" class=\"medical medical_review\">&quot;Initial evaluation of the HIV-infected adult&quot;</a> and <a href=\"#H3120781750\" class=\"local\">'Special populations'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The plasma HIV RNA level (ie, viral load) and CD4 cell count. (See <a href=\"#H1723488332\" class=\"local\">'Regimens that do not include tenofovir or abacavir'</a> below and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589706622\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Abacavir'</a> and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1322358346\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Rilpivirine'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If considering <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a>, testing for HLA-B*5701 must be obtained, as individuals with this allele are at risk for developing a severe hypersensitivity reaction to this drug. (See <a href=\"topic.htm?path=abacavir-hypersensitivity-reaction\" class=\"medical medical_review\">&quot;Abacavir hypersensitivity reaction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The impact of factors related to the regimen itself (eg, pill burden, pill size, potential for drug interactions, <span class=\"nowrap\">food/fasting</span> requirements). (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug availability and cost. (See <a href=\"topic.htm?path=the-impact-of-antiretroviral-therapy-on-morbidity-and-mortality-of-hiv-infection-in-resource-limited-settings#H1275953246\" class=\"medical medical_review\">&quot;The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings&quot;, section on 'Recommendations from the World Health Organization'</a>.)</p><p/><p>Baseline drug resistance testing should also be performed to detect the presence <span class=\"nowrap\">and/or</span> characteristics of a drug-resistant virus, which has been reported to be as high as 16 percent in treatment-na&iuml;ve patients [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1\" class=\"abstract_t\">1</a>]. Transmitted resistance to all major drug classes has been reported. However, the transmission of virus that is resistant to integrase strand transfer inhibitors (INSTIs) is rare enough that specific testing for resistance to this drug class is not required unless the source patient is known to have INSTI treatment failure or resistance. </p><p>Additional discussions of how to evaluate a patient prior to initiating antiretroviral therapy and the use of drug resistance testing are presented elsewhere. (See <a href=\"topic.htm?path=initial-evaluation-of-the-hiv-infected-adult\" class=\"medical medical_review\">&quot;Initial evaluation of the HIV-infected adult&quot;</a> and <a href=\"topic.htm?path=overview-of-hiv-drug-resistance-testing-assays\" class=\"medical medical_review\">&quot;Overview of HIV drug resistance testing assays&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1195766\"><span class=\"h1\">CHOOSING A REGIMEN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple comparative clinical trials have found that combination therapy, consisting of two nucleoside reverse transcriptase inhibitor (NRTI) agents plus a third active drug from a different class, is most effective in suppressing HIV RNA, minimizing drug toxicity, <span class=\"nowrap\">and/or</span> reducing HIV-related morbidity and mortality [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/17-20\" class=\"abstract_t\">17-20</a>]. </p><p class=\"headingAnchor\" id=\"H1291633581\"><span class=\"h2\">Preferred regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most effective antiretroviral therapy (ART) regimens contain two different NRTIs and an integrase strand transfer inhibitor (INSTI). Other effective regimens use a nucleos(t)ide combination with a different third active drug, such as a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) (<a href=\"image.htm?imageKey=ID%2F70143\" class=\"graphic graphic_table graphicRef70143 \">table 2</a>). Our approach to choosing a particular ART regimen is consistent with guideline recommendations from the United States Department of Health and Human Services (DHHS) [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1\" class=\"abstract_t\">1</a>], and the International Antiviral Society-USA (IAS-USA) [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/2\" class=\"abstract_t\">2</a>].</p><p>For most treatment-na&iuml;ve patients, we recommend one of the following regimens: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">Tenofovir alafenamide</a>&ndash;<a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a> <span class=\"nowrap\">(TAF/FTC)</span> plus either <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a>, or <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information\" class=\"drug drug_general\">Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide</a> <span class=\"nowrap\">(EVG/c/FTC/TAF)</span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dolutegravir-abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">Dolutegravir-abacavir-lamivudine</a> (for HLA-B*5701-negative patients with low cardiovascular risk) </p><p/><p>The presence of comorbid conditions (eg, reduced kidney function, HBV infection, cardiovascular disease, osteoporosis) and drug interactions (eg, certain anticonvulsants, rifamycins) may influence which regimen to use (<a href=\"image.htm?imageKey=ID%2F70143\" class=\"graphic graphic_table graphicRef70143 \">table 2</a>). The approach to choosing a regimen for patients with certain conditions is discussed below. (See <a href=\"#H3120781750\" class=\"local\">'Special populations'</a> below.). </p><p>For patients <strong>without</strong> underlying medical conditions, we generally prefer <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> plus <span class=\"nowrap\">TAF/FTC</span>. If TAF is not available, dolutegravir plus <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate-emtricitabine</a> <span class=\"nowrap\">(TDF/FTC)</span> remains an effective and well tolerated choice. The combination of <a href=\"topic.htm?path=dolutegravir-abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">dolutegravir-abacavir-lamivudine</a> (for HLA-B*5701-negative patients at low cardiovascular risk) or <span class=\"nowrap\">EVG/c/FTC/TAF</span> are also suitable options, especially for those who strongly prefer a single-daily tablet (rather than two tablets once per day) [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/9,21\" class=\"abstract_t\">9,21</a>]. The rationale for this approach, and the advantages and disadvantages of these commonly used agents are summarized elsewhere in this topic. (See <a href=\"#H86744786\" class=\"local\">'Rationale'</a> below and <a href=\"#H1195394\" class=\"local\">'Antiretroviral agents'</a> above.)</p><p>A new once-daily option, <a href=\"topic.htm?path=bictegravir-emtricitabine-and-tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">bictegravir-emtricitabine-tenofovir alafenamide</a>, was approved for use in the United States in February 2018 [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/22\" class=\"abstract_t\">22</a>]. In two randomized trials in treatment-na&iuml;ve patients, this regimen had similar efficacy to both <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> plus TAF-FTC and <a href=\"topic.htm?path=dolutegravir-abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">dolutegravir-abacavir-lamivudine</a> at 48 weeks, and no drug resistance developed [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/23,24\" class=\"abstract_t\">23,24</a>]. We prefer this regimen to the other single-pill options, since we favor the use of tenofovir rather than <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> and this combination does not require a boosting agent. However, long-term data are not yet available, and some experts may prefer one of the currently preferred single-pill regimens mentioned above pending more real-world experience with this regimen <span class=\"nowrap\">and/or</span> recommendations from guideline panels. </p><p>In certain situations (eg, when resources are limited) an INSTI may not be available. In that scenario, the patient's viral load and CD4 count must be taken into account when choosing a regimen. As an example, <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> should generally be avoided in patients with a high viral load unless <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> is the third agent. Additional information on these alternative regimens are found in the tables (<a href=\"image.htm?imageKey=ID%2F70143\" class=\"graphic graphic_table graphicRef70143 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F101813\" class=\"graphic graphic_table graphicRef101813 \">table 3</a>).</p><p class=\"headingAnchor\" id=\"H86744786\"><span class=\"h2\">Rationale</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We generally prefer a regimen that includes <a href=\"topic.htm?path=tenofovir-alafenamide-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir alafenamide-emtricitabine</a> <span class=\"nowrap\">(TAF/FTC)</span> plus an integrase inhibitor. The rationale for our approach is as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tenofovir-alafenamide-and-emtricitabine-drug-information\" class=\"drug drug_general\">Tenofovir alafenamide-emtricitabine</a><strong> as the preferred nucleoside combination </strong>&ndash; We prefer a tenofovir-containing nucleoside combination rather than one that uses <a href=\"topic.htm?path=abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">abacavir-lamivudine</a> since there is a greater body of evidence supporting the safety and tolerability of a tenofovir-containing regimen [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/4,25-28\" class=\"abstract_t\">4,25-28</a>]. In addition, the use of tenofovir avoids the need for HLA-B*5701 testing and can be given without regard to hepatitis B coinfection. (See <a href=\"#H3120781750\" class=\"local\">'Special populations'</a> below and <a href=\"#H3802481164\" class=\"local\">'Commonly used agents'</a> above and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589706004\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)'</a>.)</p><p/><p class=\"bulletIndent1\">Tenofovir is available in two preparations, <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF) and <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> (TAF). For most patients, we recommend <a href=\"topic.htm?path=tenofovir-alafenamide-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir alafenamide-emtricitabine</a> <span class=\"nowrap\">(TAF/FTC),</span> rather than <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate-emtricitabine</a> <span class=\"nowrap\">(TDF/FTC)</span>. Although there is more clinical experience with TDF, TAF is equally effective in suppressing HIV RNA, is associated with less renal toxicity, and has less effect on bone density [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/9-13\" class=\"abstract_t\">9-13</a>]. </p><p/><p class=\"bulletIndent1\">However, there are situations in which TDF is still preferred. As an example, there are drug interactions (eg, certain anticonvulsants, rifamycins) that can significantly reduce TAF, but not TDF, levels [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1\" class=\"abstract_t\">1</a>]. There is also very limited information on the use of TAF in pregnancy. (See <a href=\"#H3956580679\" class=\"local\">'Patients with tuberculosis'</a> below and <a href=\"topic.htm?path=antiretroviral-and-intrapartum-management-of-pregnant-hiv-infected-women-and-their-infants-in-resource-rich-settings\" class=\"medical medical_review\">&quot;Antiretroviral and intrapartum management of pregnant HIV-infected women and their infants in resource-rich settings&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>An INSTI as the preferred third agent</strong> &ndash; The data supporting the use of INSTIs as part of initial therapy derive from several comparative clinical trials that have demonstrated that they are equivalent, and in some cases superior, when compared with both boosted PIs and <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/5,7,9,21,29-34\" class=\"abstract_t\">5,7,9,21,29-34</a>]. As examples:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In one trial (ACTG 5257), treatment-na&iuml;ve patients were randomized to receive <span class=\"nowrap\">TDF/FTC</span> plus <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a>, ritonavir-boosted <a href=\"topic.htm?path=atazanavir-drug-information\" class=\"drug drug_general\">atazanavir</a>, or ritonavir-boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/7\" class=\"abstract_t\">7</a>]. In a combined endpoint that consisted of both virologic efficacy and tolerability, the raltegravir arm was superior to both the atazanavir and the darunavir arms.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In the SINGLE study, patients without prior treatment were randomized to receive blinded <a href=\"topic.htm?path=abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">abacavir-lamivudine</a> plus <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a>, or the single coformulated tablet of tenofovir disoproxil fumarate-emtricitabine-efavirenz [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/21\" class=\"abstract_t\">21</a>]. Dolutegravir was superior to <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>, with outcomes driven by the better tolerability of that regimen compared with the regimen that contained efavirenz.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In the FLAMINGO study, patients received <span class=\"nowrap\">TDF/FTC</span> pair plus either open label <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> or ritonavir-boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/30\" class=\"abstract_t\">30</a>]. The dolutegravir arm was superior to the darunavir arm, with the differences more pronounced in those with low CD4 cell counts or higher viral loads.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In treatment-na&iuml;ve women, two different trials compared INSTI-containing regimens (<a href=\"topic.htm?path=elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information\" class=\"drug drug_general\">elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate</a>, <a href=\"topic.htm?path=dolutegravir-abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">dolutegravir-abacavir-lamivudine</a>) with <span class=\"nowrap\">TDF/FTC</span> plus ritonavir-boosted <a href=\"topic.htm?path=atazanavir-drug-information\" class=\"drug drug_general\">atazanavir</a> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/5,35\" class=\"abstract_t\">5,35</a>], and in both trials, the INSTI regimens were superior due to better tolerability.</p><p/><p class=\"bulletIndent1\">Although there are no comparative data to favor one INSTI over the other, we generally prefer <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> plus <span class=\"nowrap\">TAF/FTC,</span> since dolutegravir has a higher barrier to resistance compared with <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a> and <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/36-38\" class=\"abstract_t\">36-38</a>], and has fewer drug interactions than <span class=\"nowrap\">EVG/c/FTC/TAF</span>. One disadvantage of using dolutegravir with <span class=\"nowrap\">TAF/FTC</span> is that this requires the use of two separate pills, rather than a single tablet, for the complete regimen. In addition, dolutegravir may have a higher rate of central nervous system side effects (insomnia, headache) than other INSTIs [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"#H3802481164\" class=\"local\">'Commonly used agents'</a> above and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1322359788\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Integrase strand transfer inhibitors (INSTIs)'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3120781750\"><span class=\"h1\">SPECIAL POPULATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although most treatment-na&iuml;ve individuals with HIV are young patients without comorbid conditions, certain patients will have a concurrent condition that can impact the choice of regimen. If more than one comorbid condition is present, the clinician should review the options for each relevant scenario and select the most appropriate combination (<a href=\"image.htm?imageKey=ID%2F101813\" class=\"graphic graphic_table graphicRef101813 \">table 3</a>). </p><p class=\"headingAnchor\" id=\"H1195773\"><span class=\"h2\">Reduced kidney function</span></p><p class=\"headingAnchor\" id=\"H3441173040\"><span class=\"h3\">Moderately reduced kidney function</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with stable but moderately reduced kidney function (estimated glomerular filtration rate [eGFR] &ge;30 to 59 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>), the regimens using <a href=\"topic.htm?path=tenofovir-alafenamide-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir alafenamide-emtricitabine</a> <span class=\"nowrap\">(TAF/FTC)</span> described above are typically used (see <a href=\"#H1291633581\" class=\"local\">'Preferred regimens'</a> above). Although there are no studies of treatment-na&iuml;ve patients with moderate renal disease starting TAF-based therapies, in a study of 242 virologically suppressed individuals with a creatinine clearance 30 to 69 <span class=\"nowrap\">mL/min</span> who were switched to <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a><span class=\"nowrap\">/<a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a>/<a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>/<a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a>,</span> patients had a stable creatinine clearance after 96 weeks [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/40\" class=\"abstract_t\">40</a>]. These data suggest that TAF can be used safely as initial therapy in patients with stable renal impairment. However, if TAF is not available, <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF) should generally be avoided. (See <a href=\"#H3802481164\" class=\"local\">'Commonly used agents'</a> above.)</p><p>Abacavir-lamivudine-dolutegravir can also be used for patients with reduced kidney function who are HLA B*5701-negative. However, for patients with an eGFR &lt;50 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>, the coformulated tablet cannot be administered since the dose of <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> needs to be adjusted based upon the degree of renal insufficiency. Detailed dosing information is available in the specific drug information topic within UpToDate.</p><p class=\"headingAnchor\" id=\"H2953499379\"><span class=\"h3\">Severely reduced kidney function</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tenofovir (TAF and TDF) should generally be avoided in patients with an eGFR &lt;30 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>. Although the risk of nephrotoxicity is reduced in patients receiving TAF compared with TDF, there are limited data evaluating TAF in patients with severe renal insufficiency. </p><p/><p>Determining the best regimen for patients with severely reduced kidney function can be difficult because such patients often have more than one comorbid illness. For such patients, treatment options include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">Abacavir</a><strong> plus </strong><a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a><strong> plus </strong><a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> &ndash; This is a preferred regimen for patients with severely reduced kidney function. However, abacavir is <strong>contraindicated</strong> in patients who are positive for HLA-B*5701 and should be avoided in patients who are at high risk for cardiovascular disease. In addition, for patients with chronic hepatitis B virus (HBV), lamivudine alone is not sufficient for treatment of HBV. The approach to treatment in <span class=\"nowrap\">HIV/HBV-coinfected</span> patients who cannot take tenofovir is discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-chronic-hepatitis-b-in-the-hiv-infected-patient#H3029510134\" class=\"medical medical_review\">&quot;Treatment of chronic hepatitis B in the HIV-infected patient&quot;, section on 'If tenofovir should not be used'</a>.)</p><p/><p class=\"bulletIndent1\">If this regimen is used, these agents cannot be administered as a coformulated tablet. <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">Lamivudine</a> need to be adjusted based upon the degree of renal insufficiency.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Regimens that do not contain </strong><a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a><strong> or tenofovir</strong> &ndash; Initial regimens that avoid the use of both abacavir and tenofovir have had mixed results in clinical trials. The most promising regimens are those that use two active drugs, such as a ritonavir-boosted protease inhibitor (PI) with either <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> or an INSTI, or <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> plus lamivudine. However, even these regimens have certain disadvantages (eg, efficacy, drug interactions, pill burden) over the recommended treatment approaches (<a href=\"image.htm?imageKey=ID%2F70143\" class=\"graphic graphic_table graphicRef70143 \">table 2</a>), or the data are too premature to recommend their widespread use. A more detailed discussion of <span class=\"nowrap\">nucleoside-limiting/sparing</span> regimens is found below. (See <a href=\"#H1723488332\" class=\"local\">'Regimens that do not include tenofovir or abacavir'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Zidovudine-lamivudine-containing regimen</strong> &ndash; A regimen that uses <a href=\"topic.htm?path=zidovudine-and-lamivudine-drug-information\" class=\"drug drug_general\">zidovudine-lamivudine</a> as the nucleoside combination can be used with a third agent from a different class since there is extensive experience using zidovudine-lamivudine. However, this combination is generally <strong>avoided </strong>since it is appears less effective than other nucleoside combinations, has an unfavorable adverse effect profile, and has not been studied in combination with integrase strand transfer inhibitors (INSTIs). In severe renal insufficiency, both <a href=\"topic.htm?path=zidovudine-drug-information\" class=\"drug drug_general\">zidovudine</a> and <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> must have doses adjusted to account for reduced renal clearance. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589709153\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Other NRTI agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Renally dosed TDF and FTC</strong> &ndash; On rare occasion, a regimen that uses renally dosed TDF plus FTC in combination with a third agent from a different class may be an option. For such patients, the decision to use TDF, and risk worsening renal function, must be weighed against the likelihood that an alternative regimen (eg, a nucleoside-sparing one) will result in sustained virologic suppression and will not be associated with an unfavorable toxicity profile. The only setting where this strategy might be advisable is in certain patients with chronic HBV, as tenofovir is the preferred treatment for <span class=\"nowrap\">HIV/HBV</span> coinfection. (See <a href=\"topic.htm?path=treatment-of-chronic-hepatitis-b-in-the-hiv-infected-patient#H489595324\" class=\"medical medical_review\">&quot;Treatment of chronic hepatitis B in the HIV-infected patient&quot;, section on 'Approach to treatment'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2108458829\"><span class=\"h2\">Hepatitis B virus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We administer a tenofovir-containing regimen to patients who have chronic HBV infection and normal or moderately reduced kidney function. <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate</a> and <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> have been found to be effective in suppressing HBV replication as well as HIV. A detailed discussion of the management of <span class=\"nowrap\">HIV/HBV</span> coinfected individuals is found elsewhere. (See <a href=\"topic.htm?path=treatment-of-chronic-hepatitis-b-in-the-hiv-infected-patient\" class=\"medical medical_review\">&quot;Treatment of chronic hepatitis B in the HIV-infected patient&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3827994979\"><span class=\"h2\">Cardiovascular disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We prefer a tenofovir-containing regimen for patients who have a history of (or are at high risk for) heart disease. Although data are conflicting, several studies have found that <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> can increase the risk of cardiovascular disease [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/4,27,41-43\" class=\"abstract_t\">4,27,41-43</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Either <a href=\"topic.htm?path=tenofovir-alafenamide-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir alafenamide-emtricitabine</a> <span class=\"nowrap\">(TAF/FTC)</span> or <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate-emtricitabine</a> <span class=\"nowrap\">(TDF/FTC)</span> can be used. Although data from clinical trials show that TAF lowers lipids less than TDF [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/12,13\" class=\"abstract_t\">12,13</a>], the clinical significance of this is unclear since the total:HDL cholesterol ratio remains the same. Furthermore, it is unknown whether the lipid-lowering effect of TDF improves clinical outcomes. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The INSTIs <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> and <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> have a largely neutral effect on cholesterol and triglycerides compared with <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> and PIs. If an INSTI is not available, <a href=\"topic.htm?path=rilpivirine-drug-information\" class=\"drug drug_general\">rilpivirine</a> can be used as the third agent for patients with a CD4 &ge;200 <span class=\"nowrap\">cells/microL</span> and a viral load &lt;100,000 <span class=\"nowrap\">copies/mL</span> since rilpivirine is also associated with minimal changes in lipids. However, rilpivirine should not be used in patients at risk for torsades de pointes. (See <a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology#H4\" class=\"medical medical_review\">&quot;Acquired long QT syndrome: Definitions, causes, and pathophysiology&quot;, section on 'Medications'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If a PI is used in patients at high cardiovascular risk, we prefer to use <a href=\"topic.htm?path=atazanavir-drug-information\" class=\"drug drug_general\">atazanavir</a> over other boosted PIs. With the exception of atazanavir, all of the ritonavir-boosted protease inhibitors (PIs) are associated with an increased risk of cardiovascular disease independent of their lipid effects [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/44\" class=\"abstract_t\">44</a>]. Furthermore, atazanavir is associated with a decreased risk of myocardial infarction compared with other antiretroviral agents [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/45\" class=\"abstract_t\">45</a>], and was shown in a prospective randomized trial to reduce carotid intima media thickness progression more than either <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> and <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/46\" class=\"abstract_t\">46</a>].</p><p/><p>More detailed discussions of antiretroviral agents, and their role in cardiovascular disease are found elsewhere. (See <a href=\"topic.htm?path=epidemiology-of-cardiovascular-disease-and-risk-factors-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology of cardiovascular disease and risk factors in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2222160923\"><span class=\"h2\">Osteoporosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate</a> (TDF) is associated with a greater loss of bone density compared with regimens that use <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> or <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> (TAF) [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/9,47\" class=\"abstract_t\">9,47</a>]. Thus, TDF should generally be avoided in patients with osteoporosis. However, if a patient cannot take <a href=\"topic.htm?path=dolutegravir-abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">dolutegravir-abacavir-lamivudine</a>, or if a TAF-containing regimen is not available, we prefer to use <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate-emtricitabine</a> as the nucleoside combination, rather than a <span class=\"nowrap\">nucleoside-limiting/sparing</span> regimen. (See <a href=\"#H1723488332\" class=\"local\">'Regimens that do not include tenofovir or abacavir'</a> below.)</p><p class=\"headingAnchor\" id=\"H3175441804\"><span class=\"h2\">Patients with adherence concerns</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients who are at high risk for taking their regimen intermittently (eg, active substance use, history of poor adherence, homelessness), we administer a regimen with a high barrier to resistance, such as a nucleos(t)ide combination with the INSTI <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> or a pharmacologically boosted PI. (See <a href=\"#H1195394\" class=\"local\">'Antiretroviral agents'</a> above.)</p><p>Patients who take a three-drug regimen with either <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> or a pharmacologically boosted PI as the third agent are unlikely to develop resistance. In general, we prefer a dolutegravir-containing regimen since clinical trials have demonstrated superiority of dolutegravir over boosted PIs [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/30,35\" class=\"abstract_t\">30,35</a>]. However, if patients are intolerant to dolutegravir (for example, because of central nervous system side effects), then pharmacologically boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> is an appropriate alternative. </p><p class=\"headingAnchor\" id=\"H3956580679\"><span class=\"h2\">Patients with tuberculosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among patients who are being treated for tuberculosis with a rifampin-containing regimen, we prefer <a href=\"topic.htm?path=efavirenz-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">efavirenz-emtricitabine-tenofovir disoproxil fumarate</a>. This combination has been used extensively in this setting, and minimizes the risk of clinically important drug interactions [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1\" class=\"abstract_t\">1</a>]. TAF should be avoided in such patients since rifamycins significantly reduce TAF levels. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1322357772\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Efavirenz'</a>.) </p><p>If <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> cannot be used, <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> or <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> can be administered and the doses adjusted as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">Raltegravir</a> should be administered as 800 mg twice daily</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">Dolutegravir</a> should be administered as 50 mg twice daily</p><p/><p>If a PI-based therapy must be used, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> should be used in place of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> in the tuberculosis regimen. A detailed discussion of the treatment of tuberculosis in HIV-infected patients is found elsewhere. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a> and <a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults\" class=\"medical medical_review\">&quot;Treatment of latent tuberculosis infection in HIV-infected adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3215294104\"><span class=\"h2\">Pregnant women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The selection of antiretroviral regimens for pregnant women is discussed elsewhere. (See <a href=\"topic.htm?path=antiretroviral-and-intrapartum-management-of-pregnant-hiv-infected-women-and-their-infants-in-resource-rich-settings#H328768\" class=\"medical medical_review\">&quot;Antiretroviral and intrapartum management of pregnant HIV-infected women and their infants in resource-rich settings&quot;, section on 'Antiretroviral selection and management'</a> and <a href=\"topic.htm?path=prevention-of-mother-to-child-hiv-transmission-in-resource-limited-settings#H472064748\" class=\"medical medical_review\">&quot;Prevention of mother-to-child HIV transmission in resource-limited settings&quot;, section on 'Recommended antiretroviral management'</a> and <a href=\"topic.htm?path=safety-and-dosing-of-antiretroviral-medications-in-pregnancy\" class=\"medical medical_review\">&quot;Safety and dosing of antiretroviral medications in pregnancy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1782994964\"><span class=\"h2\">Patients with transmitted drug resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with transmitted drug resistance, the preferred regimens can usually be used (<a href=\"image.htm?imageKey=ID%2F70143\" class=\"graphic graphic_table graphicRef70143 \">table 2</a>). One study demonstrated that response to <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a>, <a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a>, <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>, and <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> (ECF-TAF) was not reduced by the presence of baseline nucleoside reverse transcriptase inhibitor (NRTI) mutations, with the caveat that none of these patients had resistance to <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a><span class=\"nowrap\">/FTC</span> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/48\" class=\"abstract_t\">48</a>]. However, transmitted resistance to lamivudine and FTC is rare [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/49\" class=\"abstract_t\">49</a>].</p><p>In the United States, the most common type of transmitted drug resistance is to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/50\" class=\"abstract_t\">50</a>], which usually renders drugs from that class inactive. Thus, initial therapy with an NNRTI-based regimen should be avoided in patients with transmitted NNRTI resistance. </p><p>By contrast, INSTI resistance is extremely uncommon, and routine testing for baseline INSTI resistance is not recommended unless the source patient is known to have INSTI treatment failure or resistance [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1,51\" class=\"abstract_t\">1,51</a>]. More detailed information on regimen selection in the setting of INSTI resistance is found elsewhere. (See <a href=\"topic.htm?path=selecting-an-antiretroviral-regimen-for-treatment-experienced-hiv-infected-patients-who-are-failing-therapy#H495329\" class=\"medical medical_review\">&quot;Selecting an antiretroviral regimen for treatment-experienced HIV-infected patients who are failing therapy&quot;, section on 'Patients with drug-resistant virus'</a>.)</p><p>When NRTI or PI resistance is transmitted, there is typically significant residual activity that does not preclude the use of these agents. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If someone has at least one fully active NRTI, we would use <span class=\"nowrap\">TAF/FTC</span> and <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On the rare occasion when a patient has high-level transmitted NRTI resistance (eg, K65R), we generally use boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> plus <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a>. (See <a href=\"#H1723488332\" class=\"local\">'Regimens that do not include tenofovir or abacavir'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H1723488332\"><span class=\"h1\">REGIMENS THAT DO NOT INCLUDE TENOFOVIR OR ABACAVIR</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When a patient is unable to take either tenofovir (<a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> or <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a>) or <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a>, we suggest a <span class=\"nowrap\">nucleoside-limiting/sparing</span> regimen. For most patients, we administer a regimen that combines a pharmacologically boosted protease inhibitor (eg, boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a>) with either <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> or <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> (<a href=\"image.htm?imageKey=ID%2F70143\" class=\"graphic graphic_table graphicRef70143 \">table 2</a>). </p><p>It is important to assess for concomitant chronic hepatitis B virus (HBV) infection prior to initiating a regimen that does not contain tenofovir. In patients with chronic HBV, we try whenever possible to use tenofovir. The approach to regimen selection in <span class=\"nowrap\">HIV/HBV-coinfected</span> patients who cannot take tenofovir is discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-chronic-hepatitis-b-in-the-hiv-infected-patient#H202382033\" class=\"medical medical_review\">&quot;Treatment of chronic hepatitis B in the HIV-infected patient&quot;, section on 'When entecavir is used'</a>.) </p><p>We prefer to avoid <span class=\"nowrap\">nucleoside-limiting/sparing</span> regimens in treatment-na&iuml;ve patients who are able to take tenofovir or <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> because data supporting their use are limited and conflicting [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Several have evaluated the use of <span class=\"nowrap\">nucleoside-limiting/sparing</span> options in treatment-na&iuml;ve patients. Although these regimens may be effective for certain patients, there are important limitations to these options: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Ritonavir-boosted </strong><a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a><strong> plus </strong><a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a><strong>:</strong> In a randomized trial of 805 treatment-na&iuml;ve individuals, darunavir (800 mg) boosted with <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a> (100 mg) plus raltegravir (400 mg twice daily) was noninferior to an established drug combination of ritonavir-boosted darunavir plus <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate-emtricitabine</a> <span class=\"nowrap\">(TDF/FTC)</span> after 96 weeks of treatment [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/52\" class=\"abstract_t\">52</a>]. </p><p/><p class=\"bulletIndent1\">However, this nucleoside-sparing regimen should <strong>not</strong> be used in patients with a low CD4 count (&lt;200 <span class=\"nowrap\">cells/microL)</span> or an HIV RNA greater than or equal to 100,000 <span class=\"nowrap\">copies/mL</span> since such patients have an increased risk of virologic failure. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lopinavir-and-ritonavir-drug-information\" class=\"drug drug_general\">Lopinavir-ritonavir</a><strong> plus </strong><a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a><strong>: </strong>In a randomized trial of 426 patients, individuals received lopinavir boosted with <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a> in combination with either lamivudine (dual therapy) or <span class=\"nowrap\">TDF/FTC</span> (triple therapy) [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/53\" class=\"abstract_t\">53</a>]. After 48 weeks of treatment, the number of patients who achieved a viral load &lt;50 <span class=\"nowrap\">copies/mL</span> was similar between the two groups (88 versus 83 percent). </p><p/><p class=\"bulletIndent1\">Although this nucleoside-limiting regimen had a favorable effect on the viral load, there are concerns about using <a href=\"topic.htm?path=lopinavir-and-ritonavir-drug-information\" class=\"drug drug_general\">lopinavir-ritonavir</a> since it has a higher pill burden and greater gastrointestinal and lipid toxicity compared with either ritonavir-boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> or ritonavir-boosted <a href=\"topic.htm?path=atazanavir-drug-information\" class=\"drug drug_general\">atazanavir</a>. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1322359219\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Protease inhibitors (PIs)'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Darunavir-ritonavir plus </strong><a href=\"topic.htm?path=maraviroc-drug-information\" class=\"drug drug_general\">maraviroc</a><strong>:</strong> In a randomized trial of patients with pretreatment documentation of CCR5 virus, participants received either maraviroc or <span class=\"nowrap\">TDF/FTC,</span> both in combination with ritonavir-boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/54\" class=\"abstract_t\">54</a>]. The maraviroc arm was inferior to <span class=\"nowrap\">TDF/FTC,</span> with a lower rate of virologic suppression. As a result, this combination should not be used in treatment-na&iuml;ve patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dolutegravir-lamivudine</strong>: A single-arm study evaluating the use of <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> plus <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> was conducted in 120 treatment-na&iuml;ve patients with a median CD4 count 387 <span class=\"nowrap\">cells/microL</span> and HIV-1 RNA of 4.61 log10 <span class=\"nowrap\">copies/mL</span> [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/55\" class=\"abstract_t\">55</a>]. Three patients had virologic failure, each had undetectable plasma&nbsp;dolutegravir&nbsp;at one or more time points, and the M184V reverse transcriptase and <span class=\"nowrap\">R263R/K</span> integrase mutations developed in one participant.</p><p/><p>It is not known if the results of some of these clinical trials can be extrapolated to agents that are typically preferred (eg, <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> rather than <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a>, ritonavir-boosted <a href=\"topic.htm?path=darunavir-drug-information\" class=\"drug drug_general\">darunavir</a> rather than <a href=\"topic.htm?path=lopinavir-and-ritonavir-drug-information\" class=\"drug drug_general\">lopinavir-ritonavir</a>). However, we prefer regimens that are easier to administer (eg, once versus twice daily), are better tolerated (eg, pharmacologically boosted darunavir versus lopinavir-ritonavir), and would be expected to be equally potent. </p><p>There may be potential advantages of using a regimen that does not contain tenofovir or <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> in patients who have a suppressed viral load on their initial regimen. The use of two-drug regimens in this setting is discussed elsewhere.</p><p class=\"headingAnchor\" id=\"H1200026\"><span class=\"h1\">ANTIRETROVIRAL AGENTS AND COMBINATIONS TO AVOID</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Certain antiretroviral agents, or combinations of antiretroviral medications, should not be used because of toxicity, lack of efficacy, or drug antagonism. A more detailed discussion of the individual agents is found elsewhere. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2245757441\"><span class=\"h2\">Nucleoside reverse transcriptase inhibitors</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=stavudine-drug-information\" class=\"drug drug_general\">Stavudine</a> and <a href=\"topic.htm?path=didanosine-drug-information\" class=\"drug drug_general\">didanosine</a> are generally avoided given concerns of mitochondrial toxicity, lipodystrophy, and neuropathy. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589709153\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Other NRTI agents'</a> and <a href=\"topic.htm?path=mitochondrial-toxicity-of-hiv-nucleoside-reverse-transcriptase-inhibitors\" class=\"medical medical_review\">&quot;Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tenofovir and <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> do not provide additive or synergistic activity when used together, and may increase the risk of resistance to both drugs with virologic failure [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/56\" class=\"abstract_t\">56</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">Lamivudine</a> and <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a> should not be used together since these individual agents are similar with the same primary resistance mutation (ie, M184V). (See <a href=\"topic.htm?path=interpretation-of-hiv-drug-resistance-testing\" class=\"medical medical_review\">&quot;Interpretation of HIV drug resistance testing&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Regimens that include three nucleoside reverse transcriptase inhibitors (NRTIs) are <strong>not </strong>as effective as regimens that combine drugs from different classes, and are not recommended [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/56-58\" class=\"abstract_t\">56-58</a>].</p><p/><p class=\"headingAnchor\" id=\"H4288979240\"><span class=\"h2\">Non-nucleoside reverse transcriptase inhibitors</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the United States, guidelines no longer recommended <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a> for the initial treatment of HIV infection in treatment-na&iuml;ve patients. However, in certain settings (eg, resource-limited), it is still used as an alternative third agent [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/59\" class=\"abstract_t\">59</a>]. (See <a href=\"topic.htm?path=the-impact-of-antiretroviral-therapy-on-morbidity-and-mortality-of-hiv-infection-in-resource-limited-settings#H1275953246\" class=\"medical medical_review\">&quot;The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings&quot;, section on 'Recommendations from the World Health Organization'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The combination of <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> and <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a> together produces more side effects and is less efficacious than standard regimens with either drug alone [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/60\" class=\"abstract_t\">60</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=etravirine-drug-information\" class=\"drug drug_general\">Etravirine</a> has not been studied in large randomized clinical trials in treatment-na&iuml;ve patients and is thus not recommended for such patients [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"headingAnchor\" id=\"H457304158\"><span class=\"h2\">Protease inhibitors</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Agents not commonly used: <a href=\"topic.htm?path=nelfinavir-drug-information\" class=\"drug drug_general\">Nelfinavir</a>, <a href=\"topic.htm?path=indinavir-drug-information\" class=\"drug drug_general\">indinavir</a> (boosted or unboosted), <a href=\"topic.htm?path=fosamprenavir-drug-information\" class=\"drug drug_general\">fosamprenavir</a>, <a href=\"topic.htm?path=tipranavir-drug-information\" class=\"drug drug_general\">tipranavir</a>, and <a href=\"topic.htm?path=saquinavir-drug-information\" class=\"drug drug_general\">saquinavir</a> are no longer recommended by any guideline for initial treatment of HIV-infected patients [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dual protease inhibitor combinations are not recommended for initial HIV therapy since they are often associated with significant lipid abnormalities.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atazanavir-drug-information\" class=\"drug drug_general\">Atazanavir</a> should be administered with a pharmacologic boosting agent, especially if given with tenofovir. </p><p/><p class=\"headingAnchor\" id=\"H2974167218\"><span class=\"h2\">Other agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, initial regimens containing <a href=\"topic.htm?path=maraviroc-drug-information\" class=\"drug drug_general\">maraviroc</a> have not been as effective as comparators [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/54,61\" class=\"abstract_t\">54,61</a>]. As a result, we do not use maraviroc in initial therapy.</p><p class=\"headingAnchor\" id=\"H1200825\"><span class=\"h1\">PROVIDER EXPERTISE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of antiretroviral therapy (ART) is complex and should be delivered by, or in consultation with, providers with specific training. Multiple studies have shown that provider experience correlates with better patient outcomes [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/62-66\" class=\"abstract_t\">62-66</a>]. The HIV-medicine association (HIVMA) of the Infectious Diseases Society of America (IDSA) defines an &quot;HIV provider&quot; as a physician with board certification or equivalent in one of the medical <span class=\"nowrap\">specialties/subspecialties</span> recognized by the American Board of Medical Specialties or the American Osteopathic Association; the physician should have cared for at least 25 active patients with HIV infection during the preceding 36 months and should have had at least 40 hours of continuing medical education on HIV specific subject matter during the same time period [<a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/67\" class=\"abstract_t\">67</a>]. Significant clinical experience in HIV medicine over at least five years should be considered in the absence of board certification.</p><p class=\"headingAnchor\" id=\"H3119168540\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hiv-treatment-in-nonpregnant-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: HIV treatment in nonpregnant adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=starting-treatment-for-hiv-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Starting treatment for HIV (The Basics)&quot;</a> and <a href=\"topic.htm?path=hiv-aids-the-basics\" class=\"medical medical_basics\">&quot;Patient education: HIV/AIDS (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=initial-treatment-of-hiv-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Initial treatment of HIV (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=tips-for-taking-hiv-medications-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Tips for taking HIV medications (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=testing-for-hiv-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Testing for HIV (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H1201014\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The optimal goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortality (from both infectious and noninfectious causes) and to prevent the transmission of HIV to others. To achieve and sustain these goals, ART should result in maximal suppression of HIV RNA. (See <a href=\"#H1195261\" class=\"local\">'Goals of therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ART should be offered to all HIV-infected patients, including asymptomatic individuals, regardless of their immune status (ie, CD4 count). (See <a href=\"#H1263878448\" class=\"local\">'Whom to treat'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are more than 25 antiretroviral medications from six major classes currently available for the management of HIV-infected patients (<a href=\"image.htm?imageKey=ID%2F60927\" class=\"graphic graphic_table graphicRef60927 \">table 1</a>). The most commonly used antiretroviral agents for treatment-na&iuml;ve patients include nucleoside reverse transcriptase inhibitors (NRTIs), integrase inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). (See <a href=\"#H1195394\" class=\"local\">'Antiretroviral agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To optimize individual regimens, we evaluate the treatment-na&iuml;ve HIV-infected patient for the presence or absence of renal insufficiency, chronic hepatitis B virus infection, heart disease, and, if <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a> is being considered, the HLA-B*5701 allele. Abacavir is <strong>contraindicated</strong> if the patient is positive for the HLA-B*5701 allele since persons who test positive for HLA-B*5701 are at high risk for developing an abacavir hypersensitivity reaction. Baseline drug resistance testing should also be performed to detect the presence <span class=\"nowrap\">and/or</span> characteristics of a drug-resistant virus. This testing should include reverse transcriptase (nucleoside and nonnucleoside reverse transcriptase) and protease inhibitor resistance; resistance testing for INSTIs is not required unless the source patient is known to have INSTI treatment failure or resistance. (See <a href=\"#H1195505\" class=\"local\">'Considerations prior to initiating treatment'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For most treatment-na&iuml;ve patients, we recommend a regimen of tenofovir-emtricitabine, and an INSTI (eg, <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a>, <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a>, or <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a> boosted with <a href=\"topic.htm?path=cobicistat-drug-information\" class=\"drug drug_general\">cobicistat</a>), or a regimen of <a href=\"topic.htm?path=dolutegravir-abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">dolutegravir-abacavir-lamivudine</a> (but only if the patient is HLA-B*5701-negative) (<a href=\"image.htm?imageKey=ID%2F70143\" class=\"graphic graphic_table graphicRef70143 \">table 2</a>) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). Clinical trial data support the use of each of these regimens. (See <a href=\"#H1291633581\" class=\"local\">'Preferred regimens'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If a tenofovir-containing regimen is used, we recommend <a href=\"topic.htm?path=tenofovir-alafenamide-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir alafenamide-emtricitabine</a> <span class=\"nowrap\">(TAF/FTC)</span> rather than <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate-emtricitabine</a> (TDF-FTC) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). <span class=\"nowrap\">TAF/FTC</span> is associated with less renal toxicity and has less effect on bone density compared with <span class=\"nowrap\">TDF/FTC</span>. However, there are certain drug interactions (eg, anticonvulsants, rifamycins), which can significantly reduce TAF, but not TDF levels. (See <a href=\"#H86744786\" class=\"local\">'Rationale'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The ultimate choice of regimen depends in part upon the presence of concurrent conditions. If more than one comorbid condition is present, the clinician must review the options for each relevant scenario and select the most appropriate combination (<a href=\"image.htm?imageKey=ID%2F70143\" class=\"graphic graphic_table graphicRef70143 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F101813\" class=\"graphic graphic_table graphicRef101813 \">table 3</a>). (See <a href=\"#H3120781750\" class=\"local\">'Special populations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For most patients who are unable to take tenofovir or <a href=\"topic.htm?path=abacavir-drug-information\" class=\"drug drug_general\">abacavir</a>, we suggest a regimen that combines either a boosted PI plus an INSTI or a boosted PI plus <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a>, rather than a different ART combination (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). However, certain regimens may not be suitable for patients with high viral loads <span class=\"nowrap\">and/or</span> low CD4 cell counts. (See <a href=\"#H1723488332\" class=\"local\">'Regimens that do not include tenofovir or abacavir'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain antiretroviral agents, or combinations of antiretroviral medications, should not be used because of toxicity, lack of efficacy, or drug antagonism. (See <a href=\"#H1200026\" class=\"local\">'Antiretroviral agents and combinations to avoid'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are a significant number of important characteristics of the currently available antiretroviral agents that the clinician should know to help determine the optimal combination of drugs for particular patient subsets. Thus, the management of ART is complex and should be delivered by, or in consultation with, providers with specific training. (See <a href=\"#H1200825\" class=\"local\">'Provider expertise'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on October 17, 2017).</li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/2\" class=\"nounderline abstract_t\">G&uuml;nthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316:191.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/3\" class=\"nounderline abstract_t\">Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS 2018; 32:17.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/4\" class=\"nounderline abstract_t\">Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/5\" class=\"nounderline abstract_t\">DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/6\" class=\"nounderline abstract_t\">Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381:735.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/7\" class=\"nounderline abstract_t\">Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014; 161:461.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/8\" class=\"nounderline abstract_t\">Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/9\" class=\"nounderline abstract_t\">Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/10\" class=\"nounderline abstract_t\">Mills A, Crofoot G Jr, McDonald C, et al. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr 2015; 69:439.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/11\" class=\"nounderline abstract_t\">Pozniak A, Arribas JR, Gathe J, et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr 2016; 71:530.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/12\" class=\"nounderline abstract_t\">Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 2016; 3:e158.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/13\" class=\"nounderline abstract_t\">Wohl D, Oka S, Clumeck N, et al. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr 2016; 72:58.</a></li><li class=\"breakAll\">Istentress prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022145s036,203045s013,205786s004lbl.pdf (Accessed on June 07, 2017).</li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/15\" class=\"nounderline abstract_t\">Fettiplace A, Stainsby C, Winston A, et al. Psychiatric Symptoms in Patients Receiving Dolutegravir. J Acquir Immune Defic Syndr 2017; 74:423.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/16\" class=\"nounderline abstract_t\">Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18:56.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/17\" class=\"nounderline abstract_t\">Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/18\" class=\"nounderline abstract_t\">Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/19\" class=\"nounderline abstract_t\">INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368:287.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/20\" class=\"nounderline abstract_t\">MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/21\" class=\"nounderline abstract_t\">Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807.</a></li><li class=\"breakAll\">Biktarvy package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf (Accessed on February 14, 2018).</li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/23\" class=\"nounderline abstract_t\">Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 2017; 390:2073.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/24\" class=\"nounderline abstract_t\">Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 2017; 390:2063.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/25\" class=\"nounderline abstract_t\">Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/26\" class=\"nounderline abstract_t\">Bansi L, Sabin C, Gilson R, et al. Virological response to initial antiretroviral regimens containing abacavir or tenofovir. J Infect Dis 2009; 200:710.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/27\" class=\"nounderline abstract_t\">Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/28\" class=\"nounderline abstract_t\">Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55:49.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/29\" class=\"nounderline abstract_t\">Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27:1771.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/30\" class=\"nounderline abstract_t\">Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/31\" class=\"nounderline abstract_t\">Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11:907.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/32\" class=\"nounderline abstract_t\">Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 62:483.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/33\" class=\"nounderline abstract_t\">Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/34\" class=\"nounderline abstract_t\">Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 63:96.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/35\" class=\"nounderline abstract_t\">Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV 2017; 4:e536.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/36\" class=\"nounderline abstract_t\">Oliveira M, Mespl&egrave;de T, Quashie PK, et al. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014; 28:813.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/37\" class=\"nounderline abstract_t\">Osterholzer DA, Goldman M. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Clin Infect Dis 2014; 59:265.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/38\" class=\"nounderline abstract_t\">Blanco JL, Varghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/39\" class=\"nounderline abstract_t\">Pe&ntilde;afiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother 2017; 72:1752.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/40\" class=\"nounderline abstract_t\">Post FA, Tebas P, Clarke A, et al. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr 2017; 74:180.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/41\" class=\"nounderline abstract_t\">Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/42\" class=\"nounderline abstract_t\">D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/43\" class=\"nounderline abstract_t\">Marcus JL, Neugebauer RS, Leyden WA, et al. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr 2016; 71:413.</a></li><li class=\"breakAll\">Ryom L, Lundgren JD, El-Sadr WM, et al. Association between cardiovascular disease &amp; contemporarily used protease inhibitors. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA [Abstract 128LB].</li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/45\" class=\"nounderline abstract_t\">LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS 2017; 31:2095.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/46\" class=\"nounderline abstract_t\">Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015; 29:1775.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/47\" class=\"nounderline abstract_t\">McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/48\" class=\"nounderline abstract_t\">Margot NA, Kitrinos KM, Fordyce M, et al. Rare emergence of drug resistance in HIV-1 treatment-na&iuml;ve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin Trials 2016; 17:78.</a></li><li class=\"breakAll\">Porter SE, Campbell E, Westheime E, et al. Correlates of drug resistance mutations in ART-naive individuals with HIV infection. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA [Abstract 477].</li><li class=\"breakAll\">Porter SE, Campbell E, Westheimer E, et al. Correlates of drug resistance mutations in ART-naive individuals with HIV infection. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA [Abstract 477].</li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/51\" class=\"nounderline abstract_t\">Koullias Y, Sax PE, Fields NF, et al. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus? Clin Infect Dis 2017; 65:1274.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/52\" class=\"nounderline abstract_t\">Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384:1942.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/53\" class=\"nounderline abstract_t\">Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 2014; 14:572.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/54\" class=\"nounderline abstract_t\">Stellbrink HJ, Le Fevre E, Carr A, et al. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. AIDS 2016; 30:1229.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/55\" class=\"nounderline abstract_t\">Taiwo BO, Zheng L, Stefanescu A, et al. ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA &lt; 500,000 copies/mL. Clin Infect Dis 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/56\" class=\"nounderline abstract_t\">Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/57\" class=\"nounderline abstract_t\">Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/58\" class=\"nounderline abstract_t\">Landman R, Descamps D, Peytavin G, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 2005; 6:291.</a></li><li class=\"breakAll\">World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.Recommendations for a publish Health approach.2016. http://www.who.int/hiv/pub/arv/arv-2016/en/ (Accessed on June 13, 2016).</li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/60\" class=\"nounderline abstract_t\">van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/61\" class=\"nounderline abstract_t\">Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201:803.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/62\" class=\"nounderline abstract_t\">Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996; 334:701.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/63\" class=\"nounderline abstract_t\">Brosgart CL, Mitchell TF, Coleman RL, et al. Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clin Infect Dis 1999; 28:14.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/64\" class=\"nounderline abstract_t\">Cunningham WE, Tisnado DM, Lui HH, et al. The effect of hospital experience on mortality among patients hospitalized with acquired immunodeficiency syndrome in California. Am J Med 1999; 107:137.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/65\" class=\"nounderline abstract_t\">Landon BE, Wilson IB, McInnes K, et al. Physician specialization and the quality of care for human immunodeficiency virus infection. Arch Intern Med 2005; 165:1133.</a></li><li><a href=\"https://www.uptodate.com/contents/selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient/abstract/66\" class=\"nounderline abstract_t\">Rackal JM, Tynan AM, Handford CD, et al. Provider training and experience for people living with HIV/AIDS. Cochrane Database Syst Rev 2011; :CD003938.</a></li><li class=\"breakAll\">http://www.hivma.org/uploadedFiles/HIVMA/Guidelines_Patient_Care/HIVMA_Standards_Practice_Guidelines/HIV_Guidelines/Guidelines_Content/Revised%20Qualified%20HIV%20Provider%20Policy%20Statement%20Approved%203%2016%2013.pdf (Accessed on December 17, 2013).</li></ol></div><div id=\"topicVersionRevision\">Topic 3773 Version 55.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1201014\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1195155\" id=\"outline-link-H1195155\">INTRODUCTION</a></li><li><a href=\"#H1195261\" id=\"outline-link-H1195261\">GOALS OF THERAPY</a></li><li><a href=\"#H1263878448\" id=\"outline-link-H1263878448\">WHOM TO TREAT</a></li><li><a href=\"#H1195394\" id=\"outline-link-H1195394\">ANTIRETROVIRAL AGENTS</a><ul><li><a href=\"#H1195401\" id=\"outline-link-H1195401\">Drug classes used in treatment-na&iuml;ve patients</a></li><li><a href=\"#H3802481164\" id=\"outline-link-H3802481164\">Commonly used agents</a></li></ul></li><li><a href=\"#H1195505\" id=\"outline-link-H1195505\">CONSIDERATIONS PRIOR TO INITIATING TREATMENT</a></li><li><a href=\"#H1195766\" id=\"outline-link-H1195766\">CHOOSING A REGIMEN</a><ul><li><a href=\"#H1291633581\" id=\"outline-link-H1291633581\">Preferred regimens</a></li><li><a href=\"#H86744786\" id=\"outline-link-H86744786\">Rationale</a></li></ul></li><li><a href=\"#H3120781750\" id=\"outline-link-H3120781750\">SPECIAL POPULATIONS</a><ul><li><a href=\"#H1195773\" id=\"outline-link-H1195773\">Reduced kidney function</a><ul><li><a href=\"#H3441173040\" id=\"outline-link-H3441173040\">- Moderately reduced kidney function</a></li><li><a href=\"#H2953499379\" id=\"outline-link-H2953499379\">- Severely reduced kidney function</a></li></ul></li><li><a href=\"#H2108458829\" id=\"outline-link-H2108458829\">Hepatitis B virus</a></li><li><a href=\"#H3827994979\" id=\"outline-link-H3827994979\">Cardiovascular disease</a></li><li><a href=\"#H2222160923\" id=\"outline-link-H2222160923\">Osteoporosis</a></li><li><a href=\"#H3175441804\" id=\"outline-link-H3175441804\">Patients with adherence concerns</a></li><li><a href=\"#H3956580679\" id=\"outline-link-H3956580679\">Patients with tuberculosis</a></li><li><a href=\"#H3215294104\" id=\"outline-link-H3215294104\">Pregnant women</a></li><li><a href=\"#H1782994964\" id=\"outline-link-H1782994964\">Patients with transmitted drug resistance</a></li></ul></li><li><a href=\"#H1723488332\" id=\"outline-link-H1723488332\">REGIMENS THAT DO NOT INCLUDE TENOFOVIR OR ABACAVIR</a></li><li><a href=\"#H1200026\" id=\"outline-link-H1200026\">ANTIRETROVIRAL AGENTS AND COMBINATIONS TO AVOID</a><ul><li><a href=\"#H2245757441\" id=\"outline-link-H2245757441\">Nucleoside reverse transcriptase inhibitors</a></li><li><a href=\"#H4288979240\" id=\"outline-link-H4288979240\">Non-nucleoside reverse transcriptase inhibitors</a></li><li><a href=\"#H457304158\" id=\"outline-link-H457304158\">Protease inhibitors</a></li><li><a href=\"#H2974167218\" id=\"outline-link-H2974167218\">Other agents</a></li></ul></li><li><a href=\"#H1200825\" id=\"outline-link-H1200825\">PROVIDER EXPERTISE</a></li><li><a href=\"#H3119168540\" id=\"outline-link-H3119168540\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H1200931\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H1201014\" id=\"outline-link-H1201014\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/3773|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/60927\" class=\"graphic graphic_table\">- Antiretroviral drugs</a></li><li><a href=\"image.htm?imageKey=ID/70143\" class=\"graphic graphic_table\">- Preferred and alternative regimens for ART-na&iuml;ve patients</a></li><li><a href=\"image.htm?imageKey=ID/101813\" class=\"graphic graphic_table\">- Choice of ART agents based upon specific clinical scenarios</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=abacavir-hypersensitivity-reaction\" class=\"medical medical_review\">Abacavir hypersensitivity reaction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">Acquired long QT syndrome: Definitions, causes, and pathophysiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiretroviral-and-intrapartum-management-of-pregnant-hiv-infected-women-and-their-infants-in-resource-rich-settings\" class=\"medical medical_review\">Antiretroviral and intrapartum management of pregnant HIV-infected women and their infants in resource-rich settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-cardiovascular-disease-and-risk-factors-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology of cardiovascular disease and risk factors in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hiv-infection-risk-factors-and-prevention-strategies\" class=\"medical medical_review\">HIV infection: Risk factors and prevention strategies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-evaluation-of-the-hiv-infected-adult\" class=\"medical medical_review\">Initial evaluation of the HIV-infected adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interpretation-of-hiv-drug-resistance-testing\" class=\"medical medical_review\">Interpretation of HIV drug resistance testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mitochondrial-toxicity-of-hiv-nucleoside-reverse-transcriptase-inhibitors\" class=\"medical medical_review\">Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hiv-drug-resistance-testing-assays\" class=\"medical medical_review\">Overview of HIV drug resistance testing assays</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">Overview of antiretroviral agents used to treat HIV</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hiv-aids-the-basics\" class=\"medical medical_basics\">Patient education: HIV/AIDS (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-hiv-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Initial treatment of HIV (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=starting-treatment-for-hiv-the-basics\" class=\"medical medical_basics\">Patient education: Starting treatment for HIV (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=testing-for-hiv-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Testing for HIV (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tips-for-taking-hiv-medications-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Tips for taking HIV medications (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=patient-monitoring-during-hiv-antiretroviral-therapy\" class=\"medical medical_review\">Patient monitoring during HIV antiretroviral therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-mother-to-child-hiv-transmission-in-resource-limited-settings\" class=\"medical medical_review\">Prevention of mother-to-child HIV transmission in resource-limited settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=safety-and-dosing-of-antiretroviral-medications-in-pregnancy\" class=\"medical medical_review\">Safety and dosing of antiretroviral medications in pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selecting-an-antiretroviral-regimen-for-treatment-experienced-hiv-infected-patients-who-are-failing-therapy\" class=\"medical medical_review\">Selecting an antiretroviral regimen for treatment-experienced HIV-infected patients who are failing therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hiv-treatment-in-nonpregnant-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: HIV treatment in nonpregnant adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-impact-of-antiretroviral-therapy-on-morbidity-and-mortality-of-hiv-infection-in-resource-limited-settings\" class=\"medical medical_review\">The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hiv-2-infection\" class=\"medical medical_review\">Treatment of HIV-2 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-chronic-hepatitis-b-in-the-hiv-infected-patient\" class=\"medical medical_review\">Treatment of chronic hepatitis B in the HIV-infected patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults\" class=\"medical medical_review\">Treatment of latent tuberculosis infection in HIV-infected adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=when-to-initiate-antiretroviral-therapy-in-hiv-infected-patients\" class=\"medical medical_review\">When to initiate antiretroviral therapy in HIV-infected patients</a></li></ul></div></div>","javascript":null}